Oral doses of 400 mg of lomefloxacin were administered once daily prior to breakfast to 10 middle-aged to elderly hospitalized patients with chronic obstructive pulmonary disease during treatment for bronchopulmonary infections. Serial plasma and sputum samples and fractional urine samples were obtained over a steady-state dosing interval. Lomefloxacin concentrations were determined in duplicate by a validated agar well diffusion microbiological assay. The maximum plasma lomefloxacin concentration (4.5 ± 1.8 mg/liter), the time of occurrence of the maximum concentration (1.7 + 1.6 h), and the apparent volume of distribution associated with the terminal phase (2.19 + 1.05 liter/kg) were comparable to the values reported for healthy, young volunteers. Compared with the data reported for young adults, the elimination half-life (12.7 ± 4.67 h) was longer and the apparent total body clearance (132 ± 36.6 ml/min/1.73 m2) was lower in middle-aged to elderly patients. These differences were most likely attributable to age-related decreases in renal function, as evidenced by the lower lomefloxacin renal clearance (70.3 ± 33.5 ml/min) in patients. The presence of acute respiratory infection per se did not appear to alter lomefloxacin pharmacokinetics. The peak lomefloxacin concentration in purulent, expectorated sputum samples of 4.3 ± 1.2 mg/liter occurred 3.1 ± 1.7 h after dose administration and subsequently declined to 1.7 ± 0.5 mg/liter at the end of the 24-h dosing interval. The percent penetration into sputum, as assessed by comparing the area under the curve for sputum and plasma samples, was 120 ± 39.8 (range, 70 to 185). The steady-state lomefloxacin concentrations in plasma and sputum samples from ill, older patients were in excess of the MICs for 90% of the strains tested of common, susceptible respiratory pathogens over most of the dosing interval.
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Because the fluoroquinolones exhibit broad-spectrum activity against gram-positive and -negative bacteria, they have become a valuable addition to the antimicrobial armamentarium against a wide variety of infections (15) . In the treatment of respiratory tract infections, however, concern about their use against streptococcal and pseudomonal pathogens has been expressed (7, 14, 20) . In general, fluoroquinolone MICs against Streptococcus pneumoniae and Pseudomonas aeruginosa are higher than those against other common respiratory pathogens and may indeed be higher than antibiotic concentrations in sputum and bronchial tissue (7) . The desirability of achieving inhibitory or bactericidal sputum antibiotic concentrations in the treatment of acute episodes of chronic bronchitis and bronchiectasis has been underscored by several clinical trials (17) . The ability of quinolones to penetrate the blood-bronchus barrier and be distributed within bronchial secretions has therefore attracted considerable attention. It appears that some variation exists in the bronchopulmonary disposition of currently available quinolones (7, 10) . The concentration of lomefloxacin in bronchial mucosal tissue has been assessed in patients undergoing bronchoscopy; the median steady-state concentration was 177% that of serum (1) . Its penetration into purulent infected sputum, however, has not been evaluated.
An additional consideration during antimicrobial therapy is the effect of the acute infectious process itself on pharma-* Corresponding author.
cokinetics. Some investigators have identified this effect as a factor which can significantly alter the systemic disposition of antibiotics (8, 9, 13) . Pneumonia in elderly patients (19) and changes in arterial oxygenation associated with pulmonary disease (6) 
RESULTS
Clinical results. Twelve patients were enrolled in this study. Two were withdrawn from the study prior to the pharmacokinetic analysis because their sputum production had diminished, rendering them unable to fulfill the required sampling protocol. Demographic characteristics of the 10 evaluable participants are shown in Table 1 . Subjects (9 males and 1 female) ranged in age from 52 to 89 years (mean Fig. 1 . The mean plasma lomefloxacin Cm. of 4.5 1.8 mg/liter occurred 1.7 ± 1.6 h after oral administration; at 12 h, the concentration had fallen to 2.1 ± 0.8 mg/liter. The minimum plasma lomefloxacin concentration (Cmin) 24 h after the dose was 1.0 ± 0.5 mg/liter. The t1,2., AUC, Vp/f, and CL/fvalues were 12.7 ± 4.67 h, 54.1 ± 20.6 m! h/liter, 2.19 ± 1.05 liter/kg, and 132 ± 36.6 ml/min/1.73 m , respectively, as shown in Table 1 . The mean urine lomefloxacin concentrations (in milligrams per liter) per collection interval were 240 ± 116 (0 to 4 h), 235 ± 120 (4 to 8 h), 236 ± 98.3 (8 to 12 h), and 187 ± 65.3 (12 to 24 h). A total of 214 ± 67.6 mg of lomefloxacin, or 53.5% of the administered dose, was recovered in urine over 24 h. CLR was 70.3 ± 33.5 ml/min/ 1.73 m2. The peak lomefloxacin concentration in purulent, expectorated sputum of 4.3 ± 1.2 mg/liter occurred 3.1 ± 1.7 h after dose administration and subsequently declined to a Cm of 1.7 ± 0.5 mg/liter at 23 h (Fig. 1) Cmin relative to that in plasma observed in our study participants may support the finding that patients with chronic bronchitis are prone to slower clearance of intrabronchial antibiotics (18) . Certain methodological difficulties inherent in the collection of sputum samples (2) must be considered in interpreting these results. It is possible that saliva may have contaminated or diluted the expectorated samples, since the concentration of lomefloxacin in saliva is slightly lower than that in serum (21) . Additionally, the pooling of sputum samples over 2-or 4-h intervals (designed to facilitate collection and accommodate the diminished production usual for bronchitis patients in the afternoon hours) may have reduced the observed sputum lomefloxacin Cm. and/or increased the T..
The MICs of lomefloxacin for 90% of the strains tested of Haemophilus influenzae, Kiebsiella pneumoniae, Moraxella catarrhalis, E. coli, Enterobacter spp., and Legionella spp. range from .0.06 to 2 mg/liter (4, 22) . These concentrations were exceeded in both plasma and sputum samples over most of the dosing interval. If the attainment of bactericidal antibiotic concentrations in sputum is essential for the treatment of pulmonary infections, then lomefloxacin's marginal activity against S. pneumoniae may limit its use in community-acquired respiratory tract infections, as has been previously described for other fluoroquinolones (7, 14, 20) .
On the basis of its activity against common gram-negative respiratory pathogens and its steady-state pharmacokinetic properties, lomefloxacin is potentially effective given once daily in the treatment of bronchopulmonary infections caused by susceptible microorganisms. Controlled efficacy trials are warranted to fully define lomefloxacin's role in these indications. 
